# **Regulation of the Actin Cytoskeleton by Thrombin in Human Endothelial Cells: Role of Rho Proteins in Endothelial Barrier Function**

# **Vale´rie Vouret-Craviari,\* Patrice Boquet,† Jacques Pouysse´gur,\* and Ellen Van Obberghen-Schilling\*‡**

\*Centre de Biochimie, Centre National de la Recherche Scientifique, UMR 6543, 06108 Nice Cedex 2, France; and <sup>†</sup>Institut National de la Santé et de la Recherche Médicale, U452 Faculté de Médecine de Nice, 06107 Nice Cedex 2, France

Submitted December 8, 1997; Accepted July 1, 1998 Monitoring Editor: Thomas D. Pollard

> Endothelial barrier function is regulated at the cellular level by cytoskeletal-dependent anchoring and retracting forces. In the present study we have examined the signal transduction pathways underlying agonist-stimulated reorganization of the actin cytoskeleton in human umbilical vein endothelial cells. Receptor activation by thrombin, or the thrombin receptor (proteinase-activated receptor 1) agonist peptide, leads to an early increase in stress fiber formation followed by cortical actin accumulation and cell rounding. Selective inhibition of thrombin-stimulated signaling systems, including Gi/o (pertussis toxin sensitive), p42/p44, and p38 MAP kinase cascades, Src family kinases, PI-3 kinase, or S6 kinase pathways had no effect on the thrombin response. In contrast, staurosporine and KT5926, an inhibitor of myosin light chain kinase, effectively blocked thrombin-induced cell rounding and retraction. The contribution of Rho to these effects was analyzed by using bacterial toxins that either activate or inhibit the GTPase. *Escherichia coli* cytotoxic necrotizing factor 1, an activator of Rho, induced the appearance of dense actin cables across cells without perturbing monolayer integrity. Accordingly, lysophosphatidic acid, an activator of Rho-dependent stress fiber formation in fibroblasts, led to reorganization of polymerized actin into stress fibers but failed to induce cell rounding. Inhibition of Rho with *Clostridium botulinum* exoenzyme C3 fused to the B fragment of diphtheria toxin caused loss of stress fibers with only partial attenuation of thrombin-induced cell rounding. The implication of Rac and Cdc42 was analyzed in transient transfection experiments using either constitutively active (V12) or dominantinterfering (N17) mutants. Expression of RacV12 mimicked the effect of thrombin on cell rounding, and RacN17 blocked the response to thrombin, whereas Cdc42 mutants were without effect. These observations suggest that Rho is involved in the maintenance of endothelial barrier function and Rac participates in cytoskeletal remodeling by thrombin in human umbilical vein endothelial cells.

# **INTRODUCTION**

Thrombin is a tightly regulated serine proteinase that plays a central role in hemostasis. Via a widely expressed receptor, proteinase-activated receptor 1 (PAR-1) (Rasmussen *et al.*, 1991; Vu *et al.*, 1991), throm-

bin also coordinates tissue repair by inducing a host of cellular responses, including platelet aggregation, endothelial cell activation, leukocyte recruitment, and smooth-muscle cell growth (reviewed in Grand *et al.*, 1996). After blood vessel injury, the endothelium becomes rapidly converted from a nonthrombogenic, noninflammatory contiguous surface to an adhesive surface with intercellular gaps that allow the passage ‡ Corresponding author. E-mail address: vanobber@unice.fr.

of soluble plasma constituents and inflammatory cells from the vascular lumen to the underlying tissue. Thrombin has been found to potently stimulate this permeability transition of the endothelium both in vivo (Johnson *et al.*, 1983; Lo *et al.*, 1985) and in cultured endothelial cells (Garcia *et al.*, 1995). In cultured cells, thrombin induces cell shape changes and gap formation in the monolayer (Laposata *et al.*, 1983). Reorganization of the actin microfilament system is a major contributor to this effect. Accordingly, Phillips (1994) has found that phallacidin, an actin-stabilizing agent, prevents thrombin-induced increases in permeability of the endothelium to albumin.

Results from previous studies have suggested that the protein kinase C pathway plays a key role in regulating the endothelial barrier. Lynch *et al.* (1990) have shown that protein kinase C activation is correlated with increased 125I-albumin clearance rates in bovine pulmonary artery endothelial cells. However, evidence of protein kinase C involvement in thrombin-induced permeability increases relies largely on the use of kinase inhibitors. Finally, myosin light chain phosphorylation by the  $Ca^{2+}/cal$ modulin-dependent myosin light chain kinase has been shown to be essential for retraction in thrombin-stimulated human umbilical vein endothelial cell (HUVEC) cultures (Wysolmerski and Lagunoff, 1990; Garcia *et al.*, 1995; Goeckeler and Wysolmerski, 1995). Nonetheless, the signaling events that underlie distinct modifications of the actin cytoskeleton induced by thrombin in these cells have not been fully delineated.

The thrombin receptor is a seven-transmembrane receptor coupled to intracellular signaling systems via heterotrimeric GTP-binding proteins (see Van Obberghen-Schilling *et al.*, 1995). Multiple G protein subtypes can be stimulated by the thrombin receptor in target cells including Gq, Gi/o, and G12 family proteins. A pertussis toxin–sensitive pathway has been implicated in cell growth stimulation (Chambard *et al.*, 1987), linking the receptor to downstream events such as activation of Ras (Van Corven *et al.*, 1993) and the p42/p44 MAP kinase module. Tyrosine phosphorylation of a number of proteins occurs in response to thrombin (Ferrell and Martin, 1988; Golden and Brugge, 1989), including adapter molecules such as Shc, which has been shown to participate in activation of the Ras/MAP kinase cascade (Chen *et al.*, 1996). The tyrosine kinases focal adhesion kinase and Src family kinases are likely to be responsible for some of these events. Finally, thrombin modulates phospholipid metabolism and generation of key second messengers in target cells. Regulation of both phospholipases and lipid kinases by thrombin has been clearly demonstrated. Activation of Gq leads to stimulation of phospholipase C, intracellular  $Ca^{2+}$  mobilization, and activation of protein kinase C. In endothelial cells, activation of phospholipase A2 is considered the ratelimiting step in thrombin-induced prostaglandin synthesis (Hong and Deykin, 1982). Lipid kinases activated by thrombin include phosphatidylinositol (PI) 3-kinase and PI (4) 5-kinase. Interestingly, thrombinstimulated PI 3-kinase and PI (4) 5-kinase activities were found to be regulated in part by the small GTPbinding protein Rho (Zhang *et al.*, 1993, 1995; Chong *et al.*, 1994). This finding is consistent with several recent observations that link lipid kinases and their phosphorylated products to regulation of the actin cytoskeleton (see Tapon and Hall, 1997).

The direct involvement of Rho family members, including Cdc42, Rac, and Rho, in regulating agonistinduced assembly of actin-based cytoskeletal structures was first demonstrated in Swiss 3T3 fibroblasts microinjected with dominant-interfering or constitutively active mutants (Ridley and Hall, 1992; Ridley *et al.*, 1992; Nobes and Hall, 1995; Tapon and Hall, 1997). In neuronal cells, Jalink *et al.* (1994) showed that Rho is a major contributor to thrombin-induced neurite retraction and cell rounding. In the present study, we have reexamined the modifications of the actin cytoskeleton induced by thrombin in confluent endothelial cells and attempted to identify the biochemical mechanisms that regulate them. Our results based on the use of a variety of inhibitors (or activators) of known thrombin-stimulated signal transduction molecules rule out the requirement of protein kinase C,  $Ca<sup>2+</sup>$  transients, Gi family proteins, PI 3-kinase, S6 kinase, and the p42/44/38 MAP kinase modules in thrombin-stimulated endothelial cell rounding and retraction. Furthermore, our observations using Rhodirected cytotoxins indicate that Rho does not control the inward-directed contractility observed in thrombin-treated endothelial cells. Rather, the Rho-dependent pathway controls cell flattening and barrier maintenance. Additional signaling pathways trigger actin polymerization beneath the plasma membrane (Rac dependent) and centripetal force generation (myosin light chain kinase dependent) required for the full effect of thrombin.

# **MATERIALS AND METHODS**

# *Materials*

Human  $\alpha$ -thrombin (3209 NIH U/mg) was a generous gift of Dr. J.W. Fenton, II (New York State Department of Health, Albany, NY). The thrombin receptor peptide corresponding to the human receptor sequence (SFLLRN) was purchased from Neosystem (Strasbourg, France). The CP-118,556 (PP1) compound was kindly provided by Dr. S.B. Kadin (Pfizer, Groton, CT). Phorbol 12,13 dibutyrate (PdBu), histamine, staurosporine, genistein, DMSO, 8-bromo-cAMP, wortmannin, rapamycin, pertussis toxin, and FITCphalloidin were from Sigma (St. Louis, MO). KT5926 was from Calbiochem (La Jolla, CA). GF 109203X was a kind gift from Dr. D. Toullec (Glaxo, Les Ulis, France) (Toullec *et al.*, 1991). The Ca<sup>2</sup> it builed (Graxo, Les Uns, France) (Touried *et ul.*, 1991). The Ca is<br>chelator bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetra-acetic acid acetoxymethyl ester (BAPTA-AM) and Texas red–conjugated antibody to mouse immunoglobulin G were obtained from Molecular Probes (Eugene, OR). LY294002, PD98059, and SB203580 were purchased respectively from Biomol Research Laboratories (Plymouth, Meeting, PA), New England Biolabs (Beverly, PA), and SmithKline Beecham Pharmaceuticals (King of Prussia, PA). Platelet-activating factor (PAF) C18 (1-*O*-octadecyl-2-acetyl-sn-glycero-3-phosphocholine) and 1-oleoyl-lysophosphatidic acid (LPA) were from Alexis (San Diego, CA) and Avanti Polar Lipids (Alabaster, AL), respectively. Anti-c-Myc monoclonal antibody (9E10) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

#### *Bacterial Toxins*

DC3B a fusion protein between *Clostridium botulinum* exoenzyme C3 and the B fragment of diphtheria toxin was purified to homogeneity as previously described (Aullo *et al.*, 1993). Highly purified cytotoxic necrotizing factor 1 (CNF1) from uropathogenic *Escherichia coli* was obtained as described (Falzano *et al.*, 1993).

#### *Cells and Culture Conditions*

Human vascular endothelial cells (HUVECs) were isolated from umbilical cord veins by collagenase perfusion as previously described (Barbieri *et al.*, 1981). Cells were grown on 1.5% gelatin (Sigma)-coated 10-mm dishes in M199 medium (Life Technologies, Gaithersburg, MD) supplemented with 20% fetal calf serum, 30  $\mu$ g/ml endothelial cell growth supplement from Sigma, 100  $\mu$ g/ml heparin (Sigma), 50 U/ml penicillin, and 50  $\mu$ g/ml streptomycin. Cells were used between the first and the fourth passages.

The human vascular endothelial cell line EA.hy926 was obtained from Dr. C.J. Edgell (University of North Carolina, Chapel Hill, NC) (Edgell *et al.*, 1983). Cells were cultured in DMEM (Life Technologies) supplemented with 20% inactivated FCS and antibiotics. Cultures were maintained at  $37^{\circ}$ C in  $5\%$  CO<sub>2</sub>.

#### *Plasmids and Transient Transfections*

Plasmids pCMVCdc42V12, pCMVCdc42N17, pEXVRac1V12, and pEXVRac1N17 were kindly provided by Dr. M. Symons (Onyx Pharmaceuticals, Richmond, CA). pEGFP-N1 was from Clontech (Palo Alto, CA). One day after plating  $(4 \times 10^5 \text{ cells}/35\text{-mm well})$ , EA.hy926 cells were transfected with  $1 \mu$ g plasmid DNA in presence of 6 <sup>m</sup>g Dac 30 (Eurogentec, Seraing, Belgium). Cells were fixed and stained for immunofluorescence 48 h later.

#### *Localization of Actin Filaments and Immunofluorescence Studies*

Human vascular endothelial cells were plated at a density of  $2 \times 10^5$ cells per 17-mm2 Lab-Tek chamber slides (Poly Labo, Strasbourg, France) coated with fibronectin (7  $\mu$ g/ml, Sigma) and grown to confluence. Two days later, cells were treated with the agonists in serum-free medium (EA.hy926 cells) or endothelial cell growth supplement–free medium (HUVEC) and fixed in a 3% paraformaldehyde/2% sucrose solution for 15 min at room temperature. After three washes in PBS, cells were permeabilized with 0.2% Triton X-100 (Sigma) for 3 min and stained. To localize F-actin filaments, cells were incubated with FITC-phalloidin (90 ng/slide) for 45–60 min at room temperature in a humid chamber. Myc-tagged Rac and Cdc42 mutants were detected using the monoclonal antibody 9E10 and a second antibody conjugated to Texas red. Fluorescence was observed with a Nikon (Garden City, NY) Diaphot fluorescence microscope.

# *Determination of Monolayer Permeability*

Endothelial cells cultured up to confluence on fibronectin-coated Transwell filters (13 mm<sup>2</sup>, 3-um pore size; Costar, Cambridge, MA) were used to assay the passage of macromolecules through the endothelial monolayer 5–6 d after seeding. Before the experiment, cells were incubated in serum-free growth medium containing 1% BSA for 1 h at 37°C. At the start of the experiment, agonists were added concomitantly with 1 mg/ml FITC-dextran (38,500 Da) to the upper compartment of the Transwell. After 15 min, samples were taken from the lower compartment and fluorescence (excitation at 492 nm and emission at 520 nm) was determined with a fluorimeter (LS-5 luminescence, spectrometer; Perkin Elmer-Cetus, Norwalk, CT). Results are expressed as the percentage of fluorescence obtained after treatment with 5 mM EGTA for 15 min.

#### **RESULTS**

#### *Thrombin Induces Rounding of Human Endothelial Cells*

Confluent monolayers of HUVECs display a faint ring of polymerized actin at their periphery when stained with FITC-phalloidin and examined by fluorescence microscopy (Figure 1A). The addition of 10 nM thrombin to cells for 15 min causes a net increase in fluorescence intensity and a striking reorganization of the actin cytoskeleton (Figure 1B). The morphological changes are characterized by the disruption of cell– cell contacts, cell rounding, and the formation of gaps in the monolayer, as previously documented (Rabiet *et al.*, 1996). This effect of thrombin is mediated by a cellular receptor, because the peptide agonist (designated TRP) of the proteinase-activated thrombin receptor (PAR-1) was found to elicit the same morphological changes as thrombin in HUVEC cultures, with maximal effects being obtained at 100  $\mu$ M (Figure 1C). Rabiet *et al.* (1996) have reported that EA.hy926 cells, an established line of HUVECs (Edgell *et al.*, 1983), are remarkably sensitive to the morphogenic action of thrombin. As shown in Figure 1D–F, changes in the actin cytoskeleton of EA.hy926 cells in response to thrombin or TRP are similar to those observed in HUVECs. Therefore, the analyses described below were performed both on this cell line and on HUVEC cultures.

A time course analysis of thrombin-induced reorganization of the actin cytoskeleton in endothelial cells is shown in Figure 2. Two minutes after thrombin addition we commonly observe an increase in stress fiber formation. Staining with an anti-vinculin antibody revealed that the newly formed stress fibers terminate at focal adhesion complexes (our unpublished observations). After 5 min it is possible to detect some round cells, but cell rounding in response to thrombin is maximal after 15–30 min. Between 2 and 15 min, a pronounced ring of F-actin accumulates at the periphery of rounding cells (Figure 2C) and focal adhesion complexes disappear. In cells that do not round up, stress fibers thicken and become more organized. We have noted that the extent of cell retraction varies slightly from culture to culture and that more cells become totally round in EA.hy926 cultures than in primary HUVEC monolayers. Nonetheless, after treatment of both



**Figure 1.** Thrombin receptor (PAR-1) activation induces cytoskeletal reorganization in human endothelial cell monolayers. Primary cultured HUVECs (left panel) or the HUVEC-derived cell line EA.hy926 (right panel) were grown to confluence and treated with medium alone (A and D), 10 nM thrombin (B and E), or 100  $\mu$ M TRP (C and F) for 15 min at 37°C. Staining of the actin cytoskeleton was performed as described in MATERIALS AND METHODS. Arrowheads indicate the formation of a ring of peripheral actin, whereas arrows indicate the blebs that are present in some round cells. Photographs (magnification, 1000×) are representative of results from at least four independent experiments.

primary cultures and EA.hy926 cells with 10 nM thrombin, nearly all the cell–cell contacts become disrupted, and considerable gaps appear in the monolayer. As illustrated in Figure 2C, as cells round up they remain connected to one another by slender F-actin–containing retraction fibers. Maximum cell rounding is accompanied by the formation

of blebs in the plasma membrane (Figures 1F and 2C). Bleb formation in these cells is not an indication of apoptosis, because no FITC-annexin-V staining could be detected in cells after thrombin treatment (our unpublished results). Rather, thrombin-induced reorganization of the actin cytoskeleton is completely reversible. Three hours after exposure to



**Figure 2.** Thrombin-induced rounding of endothelial cells is preceded by stress fiber formation. Confluent EA.hy926 monolayers were stained with FITC-phalloidin after treatment with medium alone (A), 10 nM thrombin for 2 min (B) or 10 nM thrombin for 15 min (C). Photographs (magnification,  $1000\times$ ) are representative of three different experiments. Arrow indicates cell surface blebbing.

thrombin, confluent monolayers are reformed, consistent with the results of Rabiet *et al.* (1996).

We next compared the thrombin-induced cytoskeletal effects on endothelial cells with the effects induced by other agonists, including agents known to increase endothelial permeability such as phorbol esters, PAF, and histamine (reviewed in Lum and Malik, 1994). As shown in Figure 3A, b, addition of 100 nM PdBu, a phorbol ester that activates most isoforms of protein kinase C, causes the appearance of edge ruffles around

the entire perimeter of cells. In contrast to thrombin treatment, PdBu did not induce cell rounding or pronounced gap formation in the monolayer. PAF, a vasoactive lipid that is produced by endothelial cells in response to thrombin (Prescott *et al.*, 1984), causes a rapid  $(\leq 5$  min) and transient increase in stress fiber formation and peripheral F-actin staining in EA.hy926 cells (Figure 3A, c). The pattern of actin accumulation at the plasma membrane in PAF-treated cells is considerably less regular than in PdBu-treated cells, and we did note the appearance of small gaps in the monolayers. However PAF, like PdBu, does not mimic thrombin's effect on cell rounding. This finding, together with the fact that pretreatment of cells with a PAF receptor antagonist (the WEB-2170 compound from Boehringer Ingelheim, Heidelberg, Germany) does not inhibit thrombin-induced cytoskeletal changes (our unpublished results), indicates that thrombin action cannot be accounted for by PAF release.

In addition to the thrombin receptor PAR-1, endothelial cells have recently been shown to express a functional PAR-2 (Mirza *et al.*, 1996; Nystedt *et al.*, 1996; Molino *et al.*, 1997). Indeed, we found that addition of 100  $\mu$ M PAR-2 agonist peptide to EA.hy926 cells (Figure 3A, d) or to HUVECs induces the formation of stress fibers without inducing cell rounding. Histamine and LPA (Figure 3A, e and f) similarly increase the appearance of actin cables that extend across the entire cell. In contrast to thrombin, histamine and LPA do not markedly disrupt cell–cell contacts.

To evaluate the consequences of the observed agonist-induced cytoskeletal effects on endothelial barrier function, we assayed the passage of FITC-dextran through the monolayer after 15 min of treatment. As shown in Figure 3B, thrombin and the thrombin receptor agonist peptide (TRP) induced a significant increase in permeability to FITC-dextran, whereas PdBu, PAF, PAR-2 agonist, histamine, and LPA had little or no detectable effect. Thus, the ability of agonists to increase monolayer permeability in this in vitro assay correlates well with their ability to stimulate cell rounding. This system, however, may not fully reflect agonist-induced permeability changes observed in vivo, given the structural and cellular complexity of intact blood vessels.

#### *Activation of Protein Kinase C Does Not Induce Endothelial Cell Rounding*

It has been well established that thrombin activates phospholipase C in target cells generating the second messengers diacylglycerol, an endogenous activator of protein kinase C, and inositol triphosphate, which induces release of  $Ca^{2+}$  from intracellular stores (for review, see Van Obberghen-Schilling and Pouysségur,



alone (a), 100 nM PdBu (b), 1 nM PAF (c), 100  $\mu$ M PAR-2 agonist peptide (d),  $10^{-4}$  M histamine (e), or 20 ng/ml LPA (f) was added to confluent monolayers of EA.hy926 cells for 15 min (or 5 min in the case of PAF), and the actin cytoskeleton was visualized as described in MATERIALS AND METHODS. Arrows indicate membrane ruffling (b and c), and stress fibers (d–f). Photographs (magnification,  $1000\times$ ) are representative of results from three independent experiments. (B) 10 nM thrombin, 100  $\mu$ M TRP, 100 nM PdBu, 1 nM PAF, 100  $\mu$ M PAR2, 10<sup>-4</sup> M histamine, and 20 ng/ml LPA was added to confluent EA.hy926 cells grown on transwell filters, and the increase of transmonolayer permeability was determined after 15 min, as described in MATERIALS AND METHODS. Mean values  $\pm$  SE obtained from four separate filters are represented.









**Figure 4.** PKC inhibitor GF 109203X has no effect on thrombin-induced endothelial cell rounding. Confluent monolayers of EA.hy926 cells were pretreated for 30 min with the PKC inhibitor GF 109203X (D–F), and then medium (A and D), 10 nM thrombin (B and E), or 100 nM PdBu (C and F) was added to the cells for 15 min. F-actin staining was then performed as described in MATERIALS AND METHODS. Representative results from two independent experiments are shown (magnification,  $400\times$ ).

1993). A number of studies have suggested that a protein kinase C-dependent pathway is implicated in endothelial barrier function and actin reorganization in response to inflammatory mediators, including thrombin (reviewed in Lum, 1994). These studies have been based largely on the use of inhibitors such H-7, calphostin C, or staurosporine, which potently inhibit protein kinase C but also a variety of other protein kinases. We used the bisindoylmaleimide GF 109203X

(Toullec *et al.*, 1991), a more selective protein kinase C inhibitor that acts on the kinase domain (rather than the ATP binding site or the regulatory domain), to evaluate the contribution of protein kinase C in the cytoskeletal effects of thrombin. As shown in Figure 4, under conditions in which PdBu-induced ruffling is completely blocked, GF 109203X does not inhibit endothelial cell rounding induced by thrombin. Furthermore, overnight treatment of cells with PdBu to de-





The ability of thrombin to induce cell rounding and retraction in EA.hy926 cells was examined after treatment with the idicated inhibitors (or activator, in the case of 8-bromo-cAMP) of well-characterized signal transduction pathways. All compounds were added 30 minutes before the addition of 10 nM thrombin, except for pertussis toxin and SB203580, which were added  $\sim$  15 h before thrombin. Cell rounding was assessed after 15 min of thrombin action by actin staining. These results are representative of at least two independent experiments.

sensitize phorbol ester–sensitive isoforms of protein kinase C does not attenuate the response of cells to thrombin (our unpublished results). Together, these results suggest that protein kinase C activation is not sufficient to stimulate the thrombin-induced endothelial cell rounding.

BAPTA-AM was used to address the role of  $Ca^{2+}$ <sub>1</sub> in thrombin-stimulated cytoskeletal reorganization. Pretreatment of cells for  $45$  min with 10  $\mu$ M BAPTA-AM does not alter the thrombin effects (Table 1), whereas it abolishes the rapid increase of  $Ca^{2+}$  induced by thrombin (our unpublished results). Increasing concentrations of BAPTA-AM (up to 100  $\mu$ M) only slightly reduce thrombin-stimulated cell retraction but do not inhibit peripheral cell actin accumulation. Similarly, artificially elevating  $Ca^{2+}$  with thapsigargin was without effect on cell morphology and did not inhibit the response to thrombin (our unpublished results). Thus, we conclude from these experiments that the phospholipase C–protein kinase C pathway is not required for the rounding of EA.hy926 cells or primary cultured HUVECs.

#### *Involvement of Additional Signaling Pathways in Thrombin-induced Rounding of Endothelial Cells*

As summarized in Table 1, we examined the contribution of other known thrombin-stimulated signaling pathways in actin reorganization by the protease. The proliferative effects of thrombin are mediated, at least in part, by a pertussis toxin–sensitive heterotrimeric G protein (Chambard *et al.*, 1987). Inhibition of this pathway with pertussis toxin had no effect on F-actin staining in control or thrombin-stimulated cells. Elevation of cAMP with 8-bromo-cAMP, under conditions in which protein kinase A activity is maximally increased, did not prevent thrombin-induced stress fiber formation or cell rounding in EA.hy926 cultures. Similarly, the thrombin response was not altered after pretreatment with forskolin and 1-methyl-3-isobutylxanthine (our unpublished results). However, we did note that primary HUVECs are more sensitive than EA.hy926 cells to inhibitory effects of cAMP-elevating agents, consistent with results previously reported in studies on thrombin-induced endothelial barrier dysfunction (Patterson *et al.*, 1994).

Several lines of evidence suggest a link between phosphoinositide metabolism and regulation of the actin cytoskeleton. However, the PI 3-kinase pathway does not appear to mediate cytoskeletal remodeling by thrombin, because two unrelated inhibitors of PI 3-kinase activity, wortmannin and LY 294002, failed to block the actin rearrangement observed in thrombintreated cells. Furthermore, S6 kinase inhibition with rapamycin had no apparent effect on the response of cells to thrombin. We also assessed the contribution of both the p42/44 MAP kinase and the p38 MAP kinase pathways by using the inhibitors PD98059 (an inhibitor of MAPK/ERK kinase) and SB203580 (an inhibitor of the p38 MAP kinase). The lack of effect of these compounds on thrombin-induced stress fiber formation and rounding suggests that these MAP kinase modules are not required.

It was recently demonstrated that at least one tyrosine kinase is involved in LPA-induced formation of stress fibers (Ridley and Hall, 1994; Nobes *et al.*, 1995). To determine the possible involvement of tyrosine kinase(s) in thrombin-stimulated shape changes in endothelial cells, we examined the effect of genistein. As shown in Table 1, pretreatment of the cells with genistein decreases thrombin-induced cell rounding. However, tyrosine kinases of the Src family do not appear to be involved, because a recently described Src family kinase inhibitor, PP1 (Hanke *et al.*, 1996), had no effect alone on the actin cytoskeleton of endothelial cells and did not detectably modify the effect of thrombin.

In contrast, the broad-spectrum protein kinase inhibitor staurosporine potently blocked thrombin-induced cell rounding. Interestingly, it did not inhibit stress fiber formation by thrombin (Figure 5E). Rather, thrombin-induced stress fibers appeared to be denser and longer in the presence of staurosporine. Because a comparable phenotype was observed with KT5926 (Figure 5F), it is possible that myosin light chain kinase is the major target of staurosporine for this effect. It is of interest to note that we obtained the same results when the thrombin receptor peptide was used to stimulate cells rather than thrombin. Furthermore, primary HUVEC cultures behaved similarly (our unpublished results).

#### *Rho-dependent Stress Fiber Formation Favors Monolayer Integrity*

Increasing evidence indicates that regulation of the actin cytoskeleton involves small GTPases of the Rho family. It has been clearly demonstrated that Rho A activation controls the formation of stress fibers in fibroblasts (Ridley *et al.*, 1992). In neuronal cells, thrombin-induced retraction of neurites has been found to require Rho A (Jalink *et al.*, 1994). To investigate the role of Rho in the phenotypic changes induced by thrombin in HUVECs, we used Rho-modifying bacterial toxins. First we examined the consequences on the endothelial cell cytoskeleton of constitutive Rho activation with *Escherichia coli* CNF1 (Flatau *et al.*, 1997). As shown in Figure 6A, an overnight treatment of cells with  $10^{-9}$  M CNF1 induces the formation of thick transversal stress fibers. Rho activation does not lead to cell rounding; rather, CNF 1-treated cells acquire a flattened appearance. This effect correlates well with a decrease in agonist-stimulated permeability to macromolecules observed in CNF1-treated HUVECs (our unpublished results), thus providing a link between increased stress fiber formation and maintenance of endothelial permeability and suggesting that stress fibers contribute to barrier-promoting tethering forces.

Alternatively, Rho function was inhibited by incubating cells with a chimeric toxin, DC3B, composed of *Clostridium botulinum* C3 exoenzyme and the B fragment of diphtheria toxin (Aullo *et al.*, 1993). As shown in Figure 6D, preincubation of confluent HUVEC monolayers with  $10^{-7}$  M DC3B for 50 h leads to the disappearance of longitudinal stress fibers and cytoplasmic F-actin staining. Staining became restricted to the periphery of cells and revealed a modest disruption of cell–cell contacts. Under these conditions of toxin treatment  $\sim$ 75% of endogenous Rho is ADP ribosylated, as determined by an in vitro assay (our unpublished results). When DC3B-pretreated cells were stimulated with 10 nM thrombin for 15 min (Figure 6E), we observed an attenuation of cell rounding, compared with control thrombin-stimulated cells (Figure 6C). Similarly, partial inhibition of cell retraction by the toxin was observed in EA.hy926 cells. In the cell line it was clear, however, that inhibition of Rho did not inhibit actin polymerization beneath the plasma membrane, indicating that Rho may not be required for this effect. It is noteworthy that treatment of endothelial cells with the intact B fragment of diphtheria toxin, CRM197, had no effect on the cytoskeletal morphology of nontreated or thrombin-treated monolayers (our unpublished results).

# *A Rac-dependent Pathway Is Implicated in Thrombin-stimulated Cell Rounding*

We next examined the involvement of Rac and Cdc42 GTPases in thrombin-induced cytoskeletal modifications. To do so, EA.hy926 cells near confluence were transiently transfected with plasmids encoding constitutively active or dominant-interfering mutants, and their effect on the actin cytoskeleton was analyzed. Examination of control cultures expressing green fluorescent protein indicated that  $\sim$ 20% of the cells expressed the transfected construct, and the transfection conditions per se were without effect on cell morphology. The results obtained after transfection with the GTPase mutants, summarized in Figure 7A, reveal that Rac, and not Cdc42, is implicated in cell rounding by thrombin. Indeed, the expression of a constitutively active form of Rac (RacV12) led to the accumulation of cortical actin and cell rounding, in the absence of thrombin (Figure 7B, a and c). The addition of thrombin only slightly increased the number of round positive cells. A striking inhibition of thrombin-induced cell rounding and retraction was observed in cells transfected with the plasmid encoding pEXVRacN17, as shown in Figure 7B, b and d, strongly suggesting that Rac participates in the signaling pathway(s) that lead to this effect. In contrast, expression of constitutively active and dominant-interfering forms of Cdc42 had no functional consequences on either resting EA.hy926 cell morphology or thrombin-induced cytoskeletal modifications.

# **Thrombin**



**Figure 5.** Staurosporine and KT5926 pretreatment prevent the rounding of endothelial cells. Confluent EA.hy926 cells were pretreated for 30 min with 50 nM staurosporine (B and E), 1  $\mu$ M KT5926 (C and F), or DMSO alone (A) before the addition of 10 nM thrombin (D–F) for an additional 15 min. Staining of the actin cytoskeleton was then performed as described in MATERIALS AND METHODS. Photographs (magnification,  $1000\times$ ) are representative of four independent experiments.

# **DISCUSSION**

We have examined the signal-transducing systems that mediate reorganization of the actin cytoskeleton in cultured HUVECs treated with thrombin. The present findings extend earlier studies documenting the effects of thrombin and other inflammatory mediators on endothelial permeability in vitro and barrier function in vivo. Increased permeability in endothelial monolayers results from both disruption of tethering forces, arising from cell–cell junctions and cell–matrix interactions, and enhancement of cell retraction (reviewed in Lum and Malik, 1994; Garcia *et al.*, 1996). The actin cytoskeleton plays a prominent role in coordinating these events. Indeed, cell–cell adherens junctions are anchored to the actin cytoskeleton via a



Figure 6. Implication of Rho in control of the endothelial cell actin cytoskeleton. Confluent HUVEC monolayers were pretreated with 10<sup>-9</sup> M CNF1 for 16 h (A) or  $10^{-7}$  M DC3B for 50 h (D and E). Thrombin (10 nM) was added during the last 15 min of the experiment in C and E. The actin cytoskeleton was stained with FITC-phalloidin as described in MATERIALS AND METHODS. Photos (magnification, 1000×) are representative of at least four independent experiments. Arrows indicate gap formation between bordering cells.

complex network of signaling molecules and cytoskeletal proteins. The cytoplasmic tail of integrins attaches to actin stress fibers at dynamic structures called focal adhesions. Finally, contraction directed toward the cell center requires actin binding to its functional partner myosin. Thus, understanding the molecular events underlying control of the cytoskeleton is essential for understanding regulation of endothelial permeability in response to thrombin.

The effect of thrombin is extensive and reversible and mediated by the G protein-coupled thrombin receptor PAR-1, which becomes rapidly desensitized after activation (Woolkalis *et al.*, 1995). Recently, a second protease-activated thrombin receptor designated PAR-3 has been cloned (Ishihara *et al.*, 1997). We have been able to detect very low levels of PAR-3 mRNA in EA.hy926 cells and HUVECs by Northern analysis. Nonetheless, PAR-1 mRNA expression is significantly higher (our unpublished results). In contrast to PAR-1, synthetic peptides corresponding to the amino acid sequence adjacent to the proposed thrombin cleavage site of PAR-3 are unable to activate the receptor (Ishihara *et al.*, 1997). Therefore, it is impossible at present to determine the precise contribution of PAR-3 in thrombin's effect on HUVECs. However, the fact that the PAR-1 agonist peptide is a full agonist of thrombin action strongly suggests that the contribution of PAR-3 to thrombin-stimulated cytoskeletal reorganization in human endothelial cells is minimal.

Our finding that protein kinase C is not an absolute requirement for thrombin-induced cytoskeletal rearrangement in endothelial cells is based on the use of GF 109203X under conditions that completely block phorbol ester-induced cell ruffling. This result is in apparent contradiction with results from other studies addressing endothelial barrier dysfunction (Lynch *et al.*, 1990; Lum and Malik, 1994; Garcia *et al.*, 1996; Rabiet *et al.*, 1996; Aschner *et al.*, 1997). However, similar to other studies we observe inhibition of thrombin's effect using nonselective protein kinase C inhibitors such as calphostin C (our unpublished results). Because calphostin C acts on the diacyl glycerol-binding domain of protein kinase C, it is conceivable that a protein containing diacyl glycerol-binding zinc fingers, other than protein kinase C family members, may be involved in this effect.

Altogether, our results allow us to propose a model for thrombin-stimulated endothelial cell rounding, which involves multiple signaling pathways, including 1) a Rho-dependent pathway that controls stress fiber formation and cell spreading, 2) a Rac-stimulated pathway that regulates cortical actin polymerization, and 3) a myosin light chain kinase-dependent mechanism involved in cell retraction, as previously described (Garcia and Schaphorst, 1995). Whereas Rho appears to favor barrier function, the latter two events contribute to barrier dysfunction.

It has been clearly demonstrated in serum-starved 3T3 fibroblasts that formation of stress fibers and focal adhesion complexes are dependent on the activation of Rho (Ridley and Hall, 1992). More recently, results obtained in several laboratories have led to a converging hypothesis associating Rho to bundling of actin filaments via the activation of Rho kinase. It has been demonstrated that Rho kinase can phosphorylate the myosin-binding subunit of myosin phosphatase, thereby inactivating it (Kimura *et al.*, 1996). In addition, Rho kinase has been shown to phosphorylate myosin light chain directly and to activate the ATPase (Amano *et al.*, 1996). Both events lead to an increase in the phosphorylation state of myosin light chain and enhance binding of myosin to actin filaments (Chrzanowska-Wodnicka and Burridge, 1996). Accordingly, in resting endothelial cells, myosin ATPase inhibition with butanediome monoxime results in disappearance of stress fibers, disorganization of cell–cell contacts, and loss of cell adhesion to the substratum (unpublished observations).



**Figure 7.** Implication of Rac and Cdc42 in thrombin-induced cell rounding. (A) EA.hy926 cells were transfected with plasmids encoding green fluorescent protein (GFP) or myc-tagged GTPase mutants, as described in MATERIALS AND METHODS. The morphology of transfected cells, treated or not for 15 min with 10 nM thrombin, was observed, and 100 positive cells were scored (flat or round) per transfection condition. Data represent the mean of two independent experiments. (B) EA.hy926 cells were transfected with pEXVRac1V12 (a and c) or pEXVRac1N17 (b and d). Thrombin was added (10 nM) to cells shown in B and D 15 min before staining. Expression of Rac mutants was detected using anti-Myc antibody, and F-actin was stained with FITC-phalloidin.

We propose that the Rho-dependent pathway is associated with the maintenance of endothelial barrier function. This proposal is based on two observations. First, agonists that increase stress fiber formation in endothelial cells, such as LPA, PAR-2 peptide agonist, and histamine, do not increase the monolayer permeability to FITC-dextran. Second, constitutive activation of Rho by CNF1 induces prominent stress fiber formation without cell rounding, whereas inhibition of Rho by DC3B is associated with a loss of stress fibers and decreased cell adhesion. Accordingly, in primary cultured HUVECs, monolayer permeability was not increased in response to CNF1, whereas it was slightly augmented in response to DC3B. Our finding that C3 exoenzyme attenuates thrombin-stimulated endothelial cell retraction in HUVEC monolayers, without completely inhibiting it, is difficult to interpret. We verified that a significant proportion of Rho becomes ADP ribosylated in toxin-treated cells, compared with other systems (Fujihara *et al.*, 1997). It suggests that Rho may influence the outcome of other signaling pathways. It is noteworthy that Rho mediates thrombin-stimulated shape changes in different cell types. However, the nature of the changes is cell type specific. For example, in neuronal cells, Jalink *et al.* (1994) have shown that thrombin promotes neurite retraction and cell rounding, whereas in astrocytes thrombin induces cell spreading (Suidan *et al.*, 1997).





Myosin light chain phosphorylation is critical to thrombin-mediated endothelial cell contraction, as seen here by inhibition with KT5926 (see Figure 5; Wysolmerski and Lagunoff, 1990; Garcia *et al.*, 1995). The fact that, in our hands, BAPTA-AM only modestly inhibits thrombin-induced endothelial cell retraction suggests that the myosin light chain kinase(s) implicated in this response is not strictly  $Ca^{2+}/cal$ calmodulin dependent. Recently, a nonmuscle myosin light chain kinase has recently been cloned in endothelial cells (Garcia *et al.*, 1997); however, signaling pathways involved in regulating this kinase remain to be elucidated.

Finally, we propose that thrombin-induced cortical actin accumulation is necessary for cell retraction. A growing number of studies confirm a role for Cdc42 and Rac in mediating signals from extracellular agonists to actin polymerization and remodeling beneath the plasma membrane (for recent review, see Lim *et al.*, 1996; Tapon and Hall, 1997). For example, Cdc42 has been implicated in the formation of peripheral actin-containing structures including filopodia (Kozma *et al.*, 1996) and Rac in the formation of membrane ruffles by platelet-derived growth factor (Ridley

*et al.*, 1992). Rac has also been reported to promote actin polymerization after thrombin treatment of human platelets through uncapping of existing filament ends (Hartwig *et al.*, 1995). Here we demonstrate that Rac participates in cortical actin polymerization in endothelial cells challenged with thrombin. p21-activated kinases and PI kinases have been described as functional partners of this GTPase and both have been reported to be stimulated by thrombin (reviewed in Lim *et al.*, 1996). We are currently examining the role of p21-activated kinases in thrombin-induced actin remodeling in endothelial cells.

In conclusion, the studies presented here highlight the complexity of the signaling systems that modulate changes in the cell cytoskeleton of endothelial cells challenged with thrombin. In light of the finding that agents that block thrombin-induced cell retraction increase stress fiber formation in the presence of thrombin, we propose that thrombin first activates a Rhodependent pathway, which regulates barrier function, and then a Rac-dependent pathway involved in cell rounding and barrier dysfunction. In other systems, both interdependence and antagonism have been observed between Rho, Cdc42, and Rac pathways, reflecting the complexity of their regulation (see Lim *et al.*, 1996; Kozma *et al.*, 1997). Defining the molecular links between the thrombin receptor and Rho family GTPases as well as effector proteins that execute their effects remains a future challenge.

#### **ACKNOWLEDGMENTS**

We thank D. Grall for excellent technical assistance and P. Preau and Y. Fantei for the computer graphics. K.C. Malcolm is gratefully acknowledged for helpful discussions and critical reading of the manuscript. These studies were supported by the Centre National de la Recherche Scientifique and the University of Nice-Sophia Antipolis (UMR 6543), the Association pour la Recherche contre le Cancer, and the Ministère de l'Education Nationale de la Recherche et de la Technologie (grant ACC-SV 09). V.V.C. was supported by a research fellowship from the Sanofi Association for Thrombosis Research.

#### **REFERENCES**

Amano, M., Ito, M., Kimura, K., Fukata, Y., Chihara, K., Nakano, T., Matsuura, Y., and Kaibuchi, K. (1996). Phosphorylation and activation of myosin by Rho-associated kinase (Rho- kinase). J. Biol. Chem. *271*, 20246–20249.

Aschner, J.L., Lum, H., Fletcher, P.W., and Malik, A.B. (1997). Bradykinin- and thrombin-induced increases in endothelial permeability occur independently of phospholipase C but require protein kinase C activation. J. Cell. Physiol. *173*, 387–396.

Aullo, P., Giry, M., Olsnes, S., Popoff, M.R., Kocks, C., and Boquet, P. (1993). A chimeric toxin to study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament assembly. EMBO J. *12*, 921–931.

Barbieri, B., Balconi, G., Dejana, B., and Donati, M.B. (1981). Evidence that vascular endothelial cells can induce the retraction of fibrin clot. Proc. Soc. Exp. Biol. Med. *168*, 204–207.

Chambard, J.C., Paris, S., L'Allemain, G., and Pouysségur, J. (1987). Two growth factor signalling pathways in fibroblasts distinguished by pertussis toxin. Nature *326*, 800–803.

Chen, Y.-C., Grall, D., Salcini, E., Pelicci, P.G., Pouysségur, J., and Van Obberghen-Schilling, E. (1996). Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G proteincoupled thrombin receptor. EMBO J. *15*, 1037–1044.

Chong, L.D., Traynor, K.A., Bokoch, G.M., and Schwartz, M.A. (1994). The small GTP-binding protein Rho regulates a phosphatidylinositol 4-phosphate 5-kinase in mammalian cells. Cell *79*, 507–513.

Chrzanowska-Wodnicka, M., and Burridge, K. (1996). Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J. Cell Biol. *133*, 1403–1415.

Edgell, C.J., McDonald, C.C., and Graham, J.B. (1983). Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA *80*, 3734–3737.

Falzano, L., Fiorentini, C., Donelli, G., Michel, E., Kocks, C., Cossart, P., Cabanie, L., Oswald, E., and Boquet, P. (1993). Induction of phagocytic behaviour in human epithelial cells by *Escherichia coli* cytotoxic necrotizing factor type 1. Mol. Microbiol. *9*, 1247–1254.

Ferrell, J.E., Jr., and Martin, G.S. (1988). Platelet tyrosine-specific protein phosphorylation is regulated by thrombin. Mol. Cell. Biol. *8*, 3603–3610.

Flatau, G., Lemichez, E., Gauthier, M., Chardin, P., Paris, S., Florentini, C., and Boquet, P. (1997). Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. Nature *387*, 729–733.

Fujihara, H., Walker, L.A., Gong, M.C., Lemichez, E., Boquet, P., Somlyo, A.V., and Somlyo, A.P. (1997). Inhibition of RhoA translocation and calcium sensitization by in vivo ADP-ribosylation with the chimeric toxin DC3B. Mol. Biol. Cell *8*, 2437–2447.

Garcia, J.G., Davis, H.W., and Patterson, C.E. (1995). Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J. Cell. Physiol. *163*, 510–522.

Garcia, J.G., Lazar, V., Gilbert, M.L., Gallagher, P.J., and Verin, A.D. (1997). Myosin light chain kinase in endothelium: molecular cloning and regulation. Am. J. Respir. Cell Mol. Biol. *16*, 489–494.

Garcia, J.G., and Schaphorst, K.L. (1995). Regulation of endothelial cell gap formation and paracellular permeability. J. Invest. Med. *43*, 117–126.

Garcia, J.G., Verin, A.D., and Schaphorst, K.L. (1996). Regulation of thrombin-mediated endothelial cell contraction and permeability. Semin. Thromb. Hemostasis *22*, 309–315.

Goeckeler, Z.M., and Wysolmerski, R.B. (1995). Myosin light chain kinase-regulated endothelial cell contraction: the relationship between isometric tension, actin polymerization, and myosin phosphorylation. J. Cell Biol. *130*, 613–627.

Golden, A., and Brugge, J.S. (1989). Thrombin treatment induces rapid changes in tyrosine phosphorylation in platelets. Proc. Natl. Acad. Sci. USA *86*, 901–905.

Grand, R.J., Turnell, A.S., and Grabham, P.W. (1996). Cellular consequences of thrombin-receptor activation. Biochem. J. *313*, 353–368.

Hanke, J.H., Gardner, J.P., Dow, R.L., Changelian, P.S., Brissette, W.H., Weringer, E.J., Pollok, B.A., and Connelly, P.A. (1996). Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. *271*, 695–701.

Hartwig, J.H., Bokoch, G.M., Carpenter, C.L., Janmey, P.A., Taylor, L.A., Toker, A., and Stossel, T.P. (1995). Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell *82*, 643–653.

Hong, S.L., and Deykin, D. (1982). Activation of phospholipases A2 and C in pig aortic endothelial cells synthesizing prostacyclin. J. Biol. Chem. *257*, 7151–7154.

Ishihara, H., Connolly, A.J., Zeng, D., Kahn, M.L., Zheng, Y.W., Timmons, C., Tram, T., and Coughlin, S.R. (1997). Protease-activated receptor 3 is a second thrombin receptor in humans. Nature *386*, 502–506.

Jalink, K., van Corven, E., Hengeveld, T., Morii, N., Narumiya, S., and Moolenaar, W.H. (1994). Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J. Cell Biol. *126*, 801–810.

Johnson, A., Tahamont, M.V., and Malik, A.B. (1983). Thrombininduced lung vascular injury. Roles of fibrinogen and fibrinolysis. Am. Rev. Respir. Dis. *128*, 38–44.

Kimura, K., *et al*. (1996). Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science *273*, 245–248.

Kozma, R., Ahmed, S., Best, A., and Lim, L. (1996). The GTPaseactivating protein n-chimaerin cooperates with Rac1 and Cdc42Hs to induce the formation of lamellipodia and filopodia. Mol. Cell. Biol. *16*, 5069–5080.

Kozma, R., Sarner, S., Ahmed, S., and Lim, L. (1997). Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid. Mol. Cell. Biol. *17*, 1201–1211.

Laposata, M., Dovnarsky, D.K., and Shin, H.S. (1983). Thrombininduced gap formation in confluent endothelial cell monolayers in vitro. Blood *62*, 549–556.

Lim, L., Manser, E., Leung, T., and Hall, C. (1996). Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras- related Rho subfamily and its role in phosphorylation signalling pathways. Eur. J. Biochem. *242*, 171–185.

Lo, S.K., Perlman, M.B., Niehaus, G.D., and Malik, A.B. (1985). Thrombin-induced alterations in lung fluid balance in awake sheep. J. Appl. Physiol. *58*, 1421–1427.

Lum, H., and Malik, A.B. (1994). Regulation of vascular endothelial barrier function. Am. J. Physiol. *267*, L223–L241.

Lynch, J.J., Ferro, T.J., Blumenstock, F.A., Brockenauer, A.M., and Malik, A.B. (1990). Increased endothelial albumin permeability mediated by protein kinase C activation. J. Clin. Invest. *85*, 1991–1998.

Mirza, H., Yatsula, V., and Bahou, W.F. (1996). The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. J. Clin. Invest. *97*, 1705–1714.

Molino, M., Woolkalis, M.J., Reavey, C.J., Pratico, D., Andrade, G.P., Barnathan, E.S., and Brass, L.F. (1997). Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J. Biol. Chem. *272*, 11133–11141.

Nobes, C.D., and Hall, A. (1995). Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell *81*, 53–62.

Nobes, C.D., Hawkins, P., Stephens, L., and Hall, A. (1995). Activation of the small GTP-binding proteins rho and rac by growth factor receptors. J. Cell Sci. *108*, 225–233.

Nystedt, S., Ramakrishnan, V., and Sundelin, J. (1996). The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J. Biol. Chem. *271*, 14910–14915.

Patterson, C.E., Davis, H.W., Schaphorst, K.L., and Garcia, J.G. (1994). Mechanisms of cholera toxin prevention of thrombin- and PMA-induced endothelial cell barrier dysfunction. Microvasc. Res. *48*, 212–235.

Phillips, P.G. (1994). Thrombin-induced alterations in endothelial cell cytoarchitectural and functional properties. Semin. Thromb. Hemostasis *20*, 417–425.

Prescott, S.M., Zimmerman, G.A., and McIntyre, T.M. (1984). Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc. Natl. Acad. Sci. USA *81*, 3534–3538.

Rabiet, M.J., Plantier, J.L., Rival, Y., Genoux, Y., Lampugnani, M.G., and Dejana, E. (1996). Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler. Thromb. Vasc. Biol. *16*, 488–496.

Rasmussen, U.B., Vouret-Craviari, V., Jallat, S., Schlesinger, Y., Pagès, G., Pavirani, A., Lecocq, J.-P., Pouysségur, J., and Van Obberghen-Schilling, E. (1991). cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to  $Ca^{2+}$  mobilization. FEBS Lett. *288*, 123–128.

Ridley, A.J., and Hall, A. (1992). The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell *70*, 389–399.

Ridley, A.J., and Hall, A. (1994). Signal transduction pathways regulating Rho-mediated stress fibre formation: requirement for a tyrosine kinase. EMBO J. *13*, 2600–2610.

Ridley, A.J., Paterson, H.F., Johnston, C.L., Diekmann, D., and Hall, A. (1992). The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. *70*, 401–410.

Suidan, H.S., Nobes, C.D., Hall, A., and Monard, D. (1997). Astrocyte spreading in response to thrombin and lysophosphatidic acid is dependent on the Rho GTPase. Glia *21*, 244–252.

Tapon, N., and Hall, A. (1997). Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol. *9*, 86–92.

Toullec, D., *et al*. (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. *266*, 15771–15781.

Van Corven, E.J., Hordijk, P.L., Medema, R.H., Bos, J.L., and Moolenaar, W.H. (1993). Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. Proc. Natl. Acad. Sci. USA *90*, 1257–1261.

Van Obberghen-Schilling, E., and Pouysségur, J. (1993). Signaling pathways of the thrombin receptor. Thromb. Haemostasis *70*, 163– 167.

Van Obberghen-Schilling, E., Vouret-Craviari, V., Chen, Y.-H., Grall, D., Chambard, J.-C., and Pouysségur, J. (1995). Thrombin and its receptor in growth control. Ann. NY Acad. Sci. *766*, 431–441.

Vu, T.K.H., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell *64*, 1057–1068.

Woolkalis, M.J., DeMelfi, T.M., Blanchard, N., Hoxie, J.A., and Brass, L.F. (1995). Regulation of thrombin receptors on human umbilical vein endothelial cells. J. Biol. Chem. *270*, 9868–9875.

Wysolmerski, R.B., and Lagunoff, D. (1990). Involvement of myosin light-chain kinase in endothelial cell retraction. Proc. Natl. Acad. Sci. USA *87*, 16–20.

Zhang, J., King, W.G., Dillon, S., Hall, A., Feig, L., and Rittenhouse, S.E. (1993). Activation of platelet phosphyatidylinositide 3-kinase requires the small GTP-binding protein Rho. J. Biol. Chem. *268*, 22251–22254.

Zhang, J., Zhang, J., Benovic, J.L., Sugai, M., Wetzker, R., Gout, I., and Rittenhouse, S.E. (1995). Sequestration of a G-protein beta gamma subunit or ADP-ribosylation of Rho can inhibit thrombininduced activation of platelet phosphoinositide 3-kinases. J. Biol. Chem. *270*, 6589–6594.